



January 6, 2026

To All Concerned:

Company Name:	Hogy Medical Co., Ltd.
President:	Hideki Kawakubo, President and CEO
Securities code:	3593 (Tokyo Stock Exchange, Prime Market)
Inquiries:	Taisuke Fujita, Executive Vice President and CFO (Tel: +81-3-6229-1300)

(Amendment) Notice Regarding Amendment of “Notice Regarding Expression of Opinion in Support of Tender Offer for Company Shares by TCG2509 Co., Ltd. and Recommendation to Tender”

Hogy Medical Co., Ltd. (the “Company”) hereby announces as follows that there were matters to be amended with regards to a portion of the press release the Company published on December 17, 2025 titled “Notice Regarding Expression of Opinion in Support of Tender Offer for Company Shares by TCG2509 Co., Ltd. and Recommendation to Tender” (as amended by the press release published on December 25, 2025 titled “(Amendment) Notice Regarding Amendment of ‘Notice Regarding Expression of Opinion in Support of Tender Offer for Company Shares by TCG2509 Co., Ltd. and Recommendation to Tender’”; the “Opinion Expression Press Release”) because it was discovered that there was an error in the number of the shares of common stock of the Company (the “Company Shares”) held by Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”), and therefore TCG2509 Co., Ltd. (the “Offeror”) executed an amendment agreement to the tender offer agreement with GMO on January 6, 2026 stipulating that those parties would tender their Company Shares in the tender offer (the “Tender Offer”) for the Company Shares by the Offeror under the Financial Instruments and Exchange Act (Act No. 25 of 1948; as amended). Amendments are indicated with underlines.

In addition, because there were matters to be amended with regards to a portion of the press release titled “Notice Regarding Commencement of Tender Offer for the Common Stock of Hogy Medical Co., Ltd. (Securities Code: 3593) by TCG2509 Co., Ltd. (Attachment 2)” attached as a reference to the Opinion Expression Press Release, such press release has been amended as attached.

III. Details of, and Grounds, and Reasons for, the Opinion Regarding the Tender Offer

B. Grounds and Reasons for the Opinion Regarding the Tender Offer

The basis and grounds for the Opinion on the Tender Offer, particularly regarding the Offeror, are based on explanations received from the Offeror.

1. Overview of the Tender Offer

(Before amendment)

(Omitted)

Furthermore, the Offeror, with a view to enhancing the feasibility of the Transactions, entered into a tender agreement (the “Tender Agreement (GMO)”) dated December 25, 2025 with Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) (holding 2,237,900 shares, ownership ratio: 10.38%). The Tender Agreement (GMO) stipulates that: (1) GMO will tender all of its 2,237,900 Company Shares (ownership ratio: 10.38%), with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, in the Tender Offer, and (2) following the completion of the Squeeze-Out Procedures, GMO will indirectly acquire up to 5% of the economic interests in the Carlyle Fund by acquiring the limited partnership interests in a limited partnership Carlyle plans to form under the laws of the Cayman Islands (the “LP Interest Acquisition (GMO),” and together with the LP Interest Acquisition (Dalton Group), the “LP Interest Acquisition”; the specific percentage of LP interests to be acquired by GMO remains undetermined) (Note 3). The limited partnerships, whose limited partnership interests will be acquired in the LP Interest Acquisition (Dalton Group) and the LP Interest Acquisition (GMO), (including similarities and differences thereof) have not been determined.

(Omitted)

(After amendment)

(Omitted)

Furthermore, the Offeror, with a view to enhancing the feasibility of the Transactions, entered into a tender agreement (including subsequent amendments thereto; the “Tender Agreement (GMO)”) dated December 25, 2025 with Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) (holding 2,256,100 shares, ownership ratio: 10.46%). The Tender Agreement (GMO) stipulates that: (1) GMO will tender all of its 2,256,100 Company Shares (ownership ratio: 10.46%), with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, in the Tender Offer, and (2) following the completion of the Squeeze-Out Procedures, GMO will indirectly acquire up to 5% of the economic interests in the Carlyle Fund by acquiring the limited partnership interests in a limited partnership Carlyle plans to form under the laws of the Cayman Islands (the “LP Interest Acquisition (GMO),” and together with the LP Interest Acquisition (Dalton Group), the “LP Interest Acquisition”; the specific percentage of LP interests to be acquired by GMO remains undetermined) (Note 3). The limited partnerships, whose limited partnership interests will be acquired in the LP Interest Acquisition (Dalton Group) and the LP Interest Acquisition (GMO), (including similarities and differences thereof) have not been determined.

The Offeror, upon entering into the Tender Agreement (GMO), was informed by GMO that the number of the Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, was 2,237,900 shares (ownership ratio: 10.38%). Furthermore, as this number of shares matched the number stated in Amendment Report No. 4 to the Large Shareholding Report concerning the Company Shares submitted by GMO on August 5, 2024, the Tender Agreement (GMO) was entered into with the understanding that the number of the Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, was 2,237,900 shares (ownership ratio: 10.38%). Subsequently, on December 26, 2025, the Offeror received notification from GMO that the number of the Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, was found to be 2,256,100 shares (ownership ratio: 10.46%), which is 18,200 shares (ownership ratio: 0.08%) more than the 2,237,900 shares (ownership ratio: 10.38%). Consequently, on January 6, 2026, the Offeror entered into an amendment agreement with GMO to amend the Tender Agreement (GMO), which contains the amendment to the number of the Company Shares (with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager) that GMO is

obligated to tender in the Tender Offer under the Tender Agreement (GMO) from 2,237,900 shares (ownership ratio: 10.38%) to 2,256,100 shares (ownership ratio: 10.46%).

(Omitted)

2. Background, Purposes, and Decision-making Process Leading to the Implementation of the Tender Offer, and Management Policy After the Tender Offer

b. Background, Purposes, and Decision-making Process Leading to the Decision to Implement the Tender Offer by the Offeror

(Before amendment)

(Omitted)

Furthermore, the Offeror, with a view to enhancing the feasibility of the Transactions, commenced discussions with GMO on November 29, 2025 regarding their tender of the Company Shares owned by GMO in the Tender Offer, and the terms of such tender, including the LP Interest Acquisition (GMO). Subsequently, the Offeror reached an agreement with GMO on December 25, 2025, regarding GMO's tender of all Company Shares it holds in response to the Tender Offer and the terms of the Tender Agreement (GMO), including the LP Interest Acquisition (GMO).

(Omitted)

(After amendment)

(Omitted)

Furthermore, the Offeror, with a view to enhancing the feasibility of the Transactions, commenced discussions with GMO on November 29, 2025 regarding their tender of the Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, in the Tender Offer, and the terms of such tender, including the LP Interest Acquisition (GMO). Subsequently, the Offeror reached an agreement with GMO on December 25, 2025, regarding GMO's tender of all Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, in response to the Tender Offer and the terms of the Tender Agreement (GMO), including the LP Interest Acquisition (GMO).

The Offeror, upon entering into the Tender Agreement (GMO), was informed by GMO that the number of the Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, was 2,237,900 shares (ownership ratio: 10.38%). Furthermore, as this number of shares matched the number stated in Amendment Report No. 4 to the Large Shareholding Report concerning the Company Shares submitted by GMO on August 5, 2024, the Tender Agreement (GMO) was entered into with the understanding that the number of the Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, was 2,237,900 shares (ownership ratio: 10.38%). Subsequently, on December 26, 2025, the Offeror received notification from GMO that the number of the Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, was found to be 2,256,100 shares (ownership ratio: 10.46%), which is 18,200 shares (ownership ratio: 0.08%) more than the 2,237,900 shares (ownership ratio: 10.38%). Consequently, on January 6, 2026, the Offeror entered into an amendment agreement with GMO to amend the Tender Agreement (GMO).

which contains the amendment to the number of the Company Shares (with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager) that GMO is obligated to tender in the Tender Offer under the Tender Agreement (GMO) from 2,237,900 shares (ownership ratio: 10.38%) to 2,256,100 shares (ownership ratio: 10.46%).

(Omitted)

F. Measures for Ensuring the Fairness of the Tender Offer Price, Measures for Avoiding Conflicts of Interest, and Other Measures to Ensure Fairness in the Tender Offer

(Before amendment)

(Omitted)

9. Setting the Minimum Number of Shares to be Purchased to Exceed the Number Equivalent to the Majority of Minority

The Offeror has set the minimum number of shares to be purchased at 14,362,400 shares (ownership ratio: 66.62%). If the total number of tendered shares does not meet the minimum purchase number, the Offeror will not purchase any tendered shares. The minimum number of shares to be purchased (14,362,400 shares, ownership ratio: 66.62%) exceeds the sum (13,752,587 shares) of (i) the majority of (x) the number of shares (15,614,372 shares, ownership ratio: 72.42%) representing the total number of issued shares of the Company as of September 30, 2025 (22,535,463 shares), as stated in the Company's Second Quarter Financial Results Summary minus (y) the number of treasury shares held by the Company as of the same date (975,691 shares) and the number of the Company Shares held by Dalton Group that executed the Tender Agreement (5,945,400 shares) (7,807,187 shares, ownership ratio: 36.21%) and (ii) the number of the Company Shares (5,945,400 shares) held by Dalton Group, which represents the number representing a majority of the Company Shares held by shareholders of the Company who have no relationship of interest with the Offeror, i.e., the so-called "Majority of Minority." Accordingly, in consideration of the wishes of the Company's general shareholders, if the majority of shareholders who are not related parties of the Offeror do not give their consent, the Transactions, including the Tender Offer, will not take place.

Furthermore, as a result of the execution of the Tender Agreement (GMO) thereafter, if the number of Company Shares held by GMO (2,237,900 shares) is deducted, the minimum number of shares to be purchased falls slightly below the number corresponding to the so-called "Majority of Minority"; however, the shortfall is limited to 509,137 shares (ownership ratio: 2.36 %). In addition, the execution of the Tender Agreement (GMO) may be evaluated as having obtained the support for the Tender Offer from GMO, which was in the position of a general shareholder at the commencement of the Tender Offer, and, in light of the Offeror's confirmation and the terms of the Tender Agreement (GMO), it can be determined that GMO's continued indirect investment following the Transactions pursuant to the Tender Agreement (GMO) will not affect the Company's management policy following the Tender Offer as described in "c. Management Policy After the Tender Offer" above. Based on the foregoing, the Company, having received advice from its legal advisors, has determined that such change does not impair the rationality of the purpose of the Transactions, the fairness and appropriateness of the procedures related to the Transactions, and the fairness and appropriateness of the terms of the Transactions.

(Omitted)

(After amendment)

(Omitted)

9. Setting the Minimum Number of Shares to be Purchased to Exceed the Number Equivalent to the Majority of Minority

The Offeror has set the minimum number of shares to be purchased at 14,362,400 shares (ownership ratio: 66.62%). If the total number of tendered shares does not meet the minimum purchase number, the Offeror will not purchase any tendered shares. The minimum number of shares to be purchased (14,362,400 shares, ownership ratio: 66.62%) exceeds the sum (13,752,587 shares) of (i) the majority of the number of shares (15,614,372 shares, ownership ratio: 72.42%) representing the total number of issued shares of the Company as of September 30, 2025 (22,535,463 shares), as stated in the Company's Second Quarter Financial Results Summary minus (y) the number of treasury shares held by the Company as of the same date (975,691 shares) and the number of the Company Shares held by Dalton Group that executed the Tender Agreement (Dalton Group) (5,945,400 shares) (7,807,187 shares, ownership ratio: 36.21%) and (ii) the number of the Company Shares (5,945,400 shares) held by Dalton Group, which represents the number representing a majority of the Company Shares held by shareholders of the Company who have no relationship of interest with the Offeror, i.e., the so-called "Majority of Minority." Accordingly, in consideration of the wishes of the Company's general shareholders, if the majority of shareholders who are not related parties of the Offeror do not give their consent, the Transactions, including the Tender Offer, will not take place.

Furthermore, as a result of the execution of the Tender Agreement (GMO) thereafter, if the number of Company Shares held by GMO (2,256,100 shares) is deducted, the minimum number of shares to be purchased falls slightly below the number corresponding to the so-called "Majority of Minority"; however, the shortfall is limited to 518,237 shares (ownership ratio: 2.40 %). In addition, the execution of the Tender Agreement (GMO) may be evaluated as having obtained the support for the Tender Offer from GMO, which was in the position of a general shareholder at the commencement of the Tender Offer, and, in light of the Offeror's confirmation and the terms of the Tender Agreement (GMO), it can be determined that GMO's continued indirect investment following the Transactions pursuant to the Tender Agreement (GMO) will not affect the Company's management policy following the Tender Offer as described in "c. Management Policy After the Tender Offer" above. Based on the foregoing, the Company, having received advice from its legal advisors, has determined that such change does not impair the rationality of the purpose of the Transactions, the fairness and appropriateness of the procedures related to the Transactions, and the fairness and appropriateness of the terms of the Transactions.

(Omitted)

IV. Matters Relating to Material Agreements Concerning the Tender Offer

(Before amendment)

(Omitted)

3. Tender Agreement (GMO)

The Offeror has agreed with GMO, on December 25, 2025, that GMO will tender all 2,237,900 Company Shares it owns (ownership ratio: 10.38%), with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, in the Tender Offer, and has agreed to the terms described below in A through F.

The Offeror has not entered into any agreement with GMO regarding the tender of shares in the Tender Offer other than the Tender Agreement (GMO), and there are no benefits provided by the Offeror to GMO other than the monetary consideration obtained by tendering shares in the Tender Offer. The Tender Agreement (GMO) does not stipulate any preconditions for GMO's tender of shares. (Note 3)

(Omitted)

(After amendment)

(Omitted)

The Offeror has agreed with GMO, on December 25, 2025, that GMO will tender all 2,256,100 Company Shares it owns (ownership ratio: 10.46%), with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, in the Tender Offer, and has agreed to the terms described below in A through F.

The Offeror, upon entering into the Tender Agreement (GMO), was informed by GMO that the number of the Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, was 2,237,900 shares (ownership ratio: 10.38%). Furthermore, as this number of shares matched the number stated in Amendment Report No. 4 to the Large Shareholding Report concerning the Company Shares submitted by GMO on August 5, 2024, the Tender Agreement (GMO) was entered into with the understanding that the number of the Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, was 2,237,900 shares (ownership ratio: 10.38%). Subsequently, on December 26, 2025, the Offeror received notification from GMO that the number of the Company Shares, with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager, was found to be 2,256,100 shares (ownership ratio: 10.46%), which is 18,200 shares (ownership ratio: 0.08%) more than the 2,237,900 shares (ownership ratio: 10.38%). Consequently, on January 6, 2026, the Offeror entered into an amendment agreement with GMO to amend the Tender Agreement (GMO), which contains the amendment to the number of the Company Shares (with respect to which GMO has been delegated to conduct investment management with discretion as an investment manager) that GMO is obligated to tender in the Tender Offer under the Tender Agreement (GMO) from 2,237,900 shares (ownership ratio: 10.38%) to 2,256,100 shares (ownership ratio: 10.46%).

The Offeror has not entered into any agreement with GMO regarding the tender of shares in the Tender Offer other than the Tender Agreement (GMO), and there are no benefits provided by the Offeror to GMO other than the monetary consideration obtained by tendering shares in the Tender Offer. The Tender Agreement (GMO) does not stipulate any preconditions for GMO's tender of shares. (Note 3)

(Omitted)

End

(Reference)

“(Amendment) Notice Regarding Amendment of “Notice Regarding Commencement of Tender Offer for Common Stock of Hogy Medical Co., Ltd. (Securities Code: 3593)” dated January 6, 2026 (Attachment)

[Solicitation Regulations]

This Press Release is intended to express the Company's opinion regarding the Tender Offer and has not been prepared for the purpose of soliciting an offer to sell shares. If shareholders wish to make an offer to sell their shares, they should first carefully read the tender offer explanation statement concerning the Tender Offer and make an offer to sell their shares at their sole discretion. This Press Release shall neither be, nor constitute a part of, an offer or solicitation to sell, or solicitation of an offer to purchase, any securities, and neither this Press Release (or any part of this Press Release) nor its distribution shall be interpreted to constitute the basis of any agreement in relation to the Tender Offer, and this Press Release may not be relied upon at the time of entering into any such agreement.

[U.S. Regulations]

The Tender Offer will be conducted in accordance with the procedures and information disclosure standards prescribed in the Financial Instruments and Exchange Act of Japan. However, these procedures and information disclosure standards are not necessarily the same as the procedures and information disclosure standards in the U.S. In particular, Section 13(e) and Section 14(d) of the U.S. Securities Exchange Act of 1934 (as amended) and the rules prescribed thereunder do not apply to the Tender Offer; therefore, the Tender Offer is not conducted in accordance with those procedures or standards. The financial statements contained in this Press Release and reference materials thereof have not been prepared in accordance with the U.S. accounting standards. Accordingly, such financial information may not necessarily be equivalent or comparable to those prepared in accordance with the U.S. accounting standards. Moreover, as the Offeror is a company incorporated outside of the U.S. and a part of or all of its directors are non-U.S. residents, it may be difficult to enforce any rights or claims arising under the U.S. federal securities laws. It may also be impossible to commence legal actions against a non-U.S. company or its officers in a non-U.S. court on the grounds of a violation of the U.S. securities laws. Furthermore, there is no guarantee that a corporation that is based outside of the U.S. or its subsidiaries or affiliated companies may be compelled to submit themselves to the jurisdiction of a U.S. court.

All procedures for the Tender Offer shall be conducted entirely in the Japanese language. Some or all of the documents relating to the Tender Offer are or will be prepared in the English language. However, if there is any inconsistency between the document in English and the document in Japanese, the Japanese document shall prevail.

The Offeror and its affiliate (including the Company) and their respective financial advisors and the affiliates of the tender offer agent may, within their ordinary course of business and to the extent permitted under the related Japanese financial instruments and exchange laws and regulations, purchase or take actions to purchase the Company's common stock for their own account or for their customers' accounts other than through the Tender Offer prior to the commencement of, or during the purchase period of the Tender Offer in accordance with the requirements of Rule 14e-5(b) under the U.S. Securities Exchange Act of 1934. If any information concerning such purchase, etc. is disclosed in Japan, disclosure of such information in English will be made by the person conducting such purchase, etc. on the website of such person.

[Forward-Looking Statements]

This Press Release contains "forward-looking statements" as defined in Section 27A of the U.S. Securities Act of 1933 (as amended) and Section 21E of the U.S. Securities Exchange Act of 1934. It is possible that actual results may substantially differ from the projections, etc. as expressly or implicitly indicated in any "forward-looking statements" due to any known or unknown risks, uncertainties, or any other factors. Neither the Offeror nor any of its affiliates gives any assurance that such projections, etc. expressly or implicitly indicated in any "forward-looking statements" will ultimately be accurate. The "forward-looking statements" included in this Press Release have been prepared based on the information available to the Offeror as of the date of this Press Release, and unless otherwise required by applicable laws and regulations or Financial Instruments and Exchange Act, neither the Company nor any of its affiliates is obliged for updating or modifying such statements in order to reflect any future events or circumstances.

[Other Countries]

The announcement, issuance, or distribution of this Press Release may be legally restricted in some countries or territories. In such case, shareholders should be aware of and comply with such restriction. The announcement, issuance, or distribution of this Press Release shall not be interpreted as an offer to purchase or solicitation of an offer to sell share certificates concerning the Tender Offer, but shall be interpreted simply as a distribution of information.



January 6, 2026

To Whom It May Concern,

Company name: Hoky Medical Co., Ltd.
Representative: Hideki Kawakubo, President and CEO
Securities code: 3593 (Tokyo Stock Exchange, Prime Market)
Inquiries: Taisuke Fujita, Executive Vice President and CFO
(Tel: +81-3-6229-1300)

(Amendment) Notice Regarding Amendment of “Notice Regarding Commencement of Tender Offer for the Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593) by TCG2509 Co., Ltd.”

TCG2509 Co., Ltd. entered into an amendment agreement on January 6, 2026 to correct clerical errors in the number of Target Shares held by Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) in the original tender agreement dated December 25, 2025. As a result, certain information in the tender offer registration statement submitted on December 18, 2025 (including the information amended by the amendment statement to the tender offer registration statement submitted on December 25, 2025), and the public notice regarding the commencement of tender offer dated December 18, 2025 (including the information amended by the amendment statement to the tender offer registration statement submitted on December 25, 2025), attached thereto, needs to be amended. Therefore, pursuant to Article 27-8, Paragraphs 1 and 2 of the Act, the Offeror submitted the amendment statement to the tender offer registration statement. Consequently, the information contained in the “Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)” dated December 17, 2025 (including the information contained in the “Notice Regarding Amendment of ‘Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)’ and the Public Notice Regarding Commencement of Tender Offer” dated December 25, 2025), is hereby amended as set forth in the attached document.

This disclosure is being made pursuant to Article 30, Paragraph 1, Item 4 of the Order for Enforcement of the Financial Instruments and Exchange Act, based on a request from TCG2509 Co., Ltd. (the tender offeror) to Hoky Medical Co., Ltd. (the company subject to the tender offer).

(Attachment)

“Notice Regarding Amendment of “Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)” and the Public Notice Regarding

Commencement of Tender Offer” dated January 6, 2026

January 6, 2026

To Whom It May Concern,

Company Name:	TCG2509 Co., Ltd.
Representative:	Representative Director Genta Saito

(Amendment) Notice Regarding Amendment of “Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)” and the Public Notice Regarding Commencement of Tender Offer

TCG2509 Co., Ltd. (the “Offeror”) decided at a meeting of its Board of Directors held on December 17, 2025, to acquire common stock (the “Target Shares”) of Hoky Medical Co., Ltd. (Tokyo Stock Exchange (the “TSE”) Prime Market, Securities Code: 3593, the “Target”) through a tender offer (the “Tender Offer”) pursuant to the Financial Instruments and Exchange Act (Act No. 25 of 1948, as amended) (the “Act”), and commenced the Tender Offer on December 18, 2025. In connection with the Offeror entering into an amendment agreement on January 6, 2026 to correct clerical errors in the number of Target Shares held by Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) in the original tender agreement dated December 25, 2025, certain information in the tender offer registration statement submitted on December 18, 2025 (including the information amended by the amendment statement to the tender offer registration statement submitted on December 25, 2025; the “Tender Offer Registration Statement”) and the public notice regarding commencement of tender offer dated December 18, 2025, attached thereto (including the information amended by the “(Amendment) Notice Regarding Amendment of ‘Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)’ and the Public Notice Regarding Commencement of Tender Offer” announced on December 25, 2025; the “Public Notice Regarding Commencement of Tender Offer”), needs to be amended. Additionally, there were clerical errors in these documents. Therefore, pursuant to Article 27-8, Paragraphs 1 and 2 of the Act, the Offeror submitted an amendment statement to the tender offer registration statement.

Accordingly, the Offeror hereby announces that it has amended the “Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)” dated December 17, 2025 (including the information amended by the “(Amendment) Notice Regarding Amendment of ‘Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)’ and the Public Notice Regarding Commencement of Tender Offer” announced on December 25, 2025; the “Public Notice Regarding Commencement of Tender Offer”), and the Public Notice Regarding Commencement of Tender Offer, as described below.

This amendment does not change the terms and conditions set forth in Article 27-3, Paragraph 2, Item 1 of the Act. The amended portions are underlined.

[I] Amendment of the “Notice Regarding Commencement of Tender Offer for Common Stock of Hoky Medical Co., Ltd. (Securities Code: 3593)” dated December 17, 2025

II. OUTLINE OF THE TENDER OFFER

(Before the amendment)

<Text omitted>

Furthermore, the Offeror, with a view to enhancing the feasibility of the Transaction, entered into a tender agreement (the “Tender Agreement (GMO)”) dated December 25, 2025 with Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) (holding 2,237,900 shares, ownership ratio: 10.38%) The Tender Agreement (GMO) stipulates that: (1) GMO will tender all 2,237,900 Target shares (ownership ratio: 10.38%) for which GMO has been entrusted with investment management as the investment manager to the Tender Offer, and (2) following completion of the Squeeze-Out Procedures, GMO will indirectly acquire up to 5% of the economic interests in the Carlyle Fund by acquiring the limited partnership interests in a limited partnership Carlyle plans to form under the laws of the Cayman Islands (the “LP Interest Acquisition (GMO),” and together with the LP Interest Acquisition (Dalton Group), the “LP Interest Acquisition”; the specific percentage of LP interests to be acquired by GMO remains undetermined) (Note 3). The limited partnerships (including whether they are the same or different entities) that will be the subject of the acquisition of limited partnership interests in both the LP Interest Acquisition (Dalton Group) and the LP Interest Acquisition (GMO) remain undetermined.

<Text omitted>

(After the amendment)

<Text omitted>

Furthermore, the Offeror, with a view to enhancing the feasibility of the Transaction, entered into a tender agreement (including subsequent amendments thereto; the “Tender Agreement (GMO)”) dated December 25, 2025 with Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) (holding 2,256,100 shares, ownership ratio: 10.46%). The Tender Agreement (GMO) stipulates that: (1) GMO will tender all 2,256,100 Target shares (ownership ratio: 10.46%) for which GMO has been entrusted with investment management as the investment manager to the Tender Offer, and (2) following completion of the Squeeze-Out Procedures, GMO will indirectly acquire up to 5% of the economic interests in the Carlyle Fund by acquiring the limited partnership interests in a limited partnership Carlyle plans to form under the laws of the Cayman Islands (the “LP Interest Acquisition (GMO),”

and together with the LP Interest Acquisition (Dalton Group), the “LP Interest Acquisition”; the specific percentage of LP interests to be acquired by GMO remains undetermined) (Note 3). The limited partnerships (including whether they are the same or different entities) that will be the subject of the acquisition of limited partnership interests in both the LP Interest Acquisition (Dalton Group) and the LP Interest Acquisition (GMO) remain undetermined.

The Offeror, upon entering into the Tender Agreement (GMO), was informed by GMO that the number of Target Shares for which GMO had been entrusted with investment management as the investment manager was 2,237,900 shares (ownership ratio: 10.38%). Furthermore, as this number of shares matched the number stated in Amendment Report No. 4 to the Large Shareholding Report concerning the Target Shares submitted by GMO on August 5, 2024, the Tender Agreement (GMO) was entered into with the understanding that the number of Target Shares for which GMO acts as investment manager under a discretionary investment management agreement was 2,237,900 shares (ownership ratio: 10.38%). Subsequently, on December 26, 2025, the Offeror received notification from GMO that the number of Target Shares for which GMO has been entrusted with investment management as an investment manager was found to be 2,256,100 shares (ownership ratio: 10.46%), which is 18,200 shares (ownership ratio: 0.08%) more than the 2,237,900 shares (ownership ratio: 10.38%). Consequently, on January 6, 2026, the Offeror entered into an amendment agreement with GMO to amend the Tender Agreement (GMO), which contains the amendment to the number of Target Shares for which GMO, as the investment manager with delegated investment management authority, shall tender under the Tender Agreement (GMO) from 2,237,900 shares (ownership ratio: 10.38%) to 2,256,100 shares (ownership ratio: 10.46%).

<Text omitted>

III. PURPOSE OF THE TENDER OFFER

(Before the amendment)

Furthermore, the Offeror, with a view to enhance the feasibility of the Transaction, commenced discussions with GMO on November 29, 2025 regarding their tender of the Target Shares for which GMO has been entrusted with investment management as the investment manager to the Tender Offer, and the terms of such tender, including the LP Interest Acquisition (GMO). Subsequently, the Offeror reached an agreement with GMO on December 25, 2025, regarding GMO’s tender of all Target Shares for which GMO has been entrusted with investment management as the investment manager in response to this Tender Offer and the terms of the Tender Agreement (GMO), including the LP Interest Acquisition (GMO).

(After the amendment)

Furthermore, the Offeror, with a view to enhance the feasibility of the Transaction, commenced discussions with GMO on November 29, 2025 regarding their tender of the Target Shares for which GMO has been entrusted with investment management as the investment manager to the Tender Offer, and the terms of such tender, including the LP Interest Acquisition (GMO). Subsequently, the Offeror reached an agreement with GMO on December 25, 2025, regarding GMO's tender of all Target Shares for which GMO has been entrusted with investment management as the investment manager in response to this Tender Offer and the terms of the Tender Agreement (GMO), including the LP Interest Acquisition (GMO).

The Offeror, upon entering into the Tender Agreement (GMO), was informed by GMO that the number of Target Shares for which GMO had been entrusted with investment management as the investment manager was 2,237,900 shares (ownership ratio: 10.38%). Furthermore, as this number of shares matched the number stated in Amendment Report No. 4 to the Large Shareholding Report concerning the Target Shares submitted by GMO on August 5, 2024, the Tender Agreement (GMO) was entered into with the understanding that the number of Target Shares for which GMO acts as investment manager under a discretionary investment management agreement was 2,237,900 shares (ownership ratio: 10.38%). Subsequently, on December 26, 2025, the Offeror received notification from GMO that the number of Target Shares for which GMO has been entrusted with investment management as an investment manager was found to be 2,256,100 shares (ownership ratio: 10.46%), which is 18,200 shares (ownership ratio: 0.08%) more than the 2,237,900 shares (ownership ratio: 10.38%). Consequently, on January 6, 2026, the Offeror entered into an amendment agreement with GMO to amend the Tender Agreement (GMO), which contains the amendment to the number of Target Shares for which GMO, as the investment manager with delegated investment management authority, shall tender under the Tender Agreement (GMO) from 2,237,900 shares (ownership ratio: 10.38%) to 2,256,100 shares (ownership ratio: 10.46%).

[II] Amendment of the Public Notice Regarding Commencement of Tender Offer

I. PURPOSE OF THE TENDER OFFER

(Before the amendment)

<Text omitted>

Furthermore, the Offeror, with a view to enhancing the feasibility of the Transaction, entered into a tender agreement (the "Tender Agreement (GMO)") dated December 25, 2025 with Grantham, Mayo, Van Otterloo & Co. LLC ("GMO") (holding 2,237,900 shares, ownership ratio: 10.38%). The Tender Agreement (GMO) stipulates that: (1) GMO will tender all 2,237,900 Target shares (ownership ratio: 10.38%) for which GMO has been entrusted with investment management as the investment manager to the Tender Offer, and (2) following completion of the Squeeze-Out Procedures, GMO will

indirectly acquire up to 5% of the economic interests in the Carlyle Fund by acquiring the limited partnership interests in a limited partnership Carlyle plans to form under the laws of the Cayman Islands (the “LP Interest Acquisition (GMO),” and together with the LP Interest Acquisition (Dalton Group), the “LP Interest Acquisition”; the specific percentage of LP interests to be acquired by GMO remains undetermined) (Note 2). The limited partnerships (including whether they are the same or different entities) that will be the subject of the acquisition of limited partnership interests in both the LP Interest Acquisition (Dalton Group) and the LP Interest Acquisition (GMO) remain undetermined.

<Text omitted>

(After the amendment)

<Text omitted>

Furthermore, the Offeror, with a view to enhancing the feasibility of the Transaction, entered into a tender agreement (including subsequent amendments thereto; the “Tender Agreement (GMO)”) dated December 25, 2025 with Grantham, Mayo, Van Otterloo & Co. LLC (“GMO”) (holding 2,256,100 shares, ownership ratio: 10.46%). The Tender Agreement (GMO) stipulates that: (1) GMO will tender all 2,256,100 Target Shares (ownership ratio: 10.46%) for which GMO has been entrusted with investment management as the investment manager to the Tender Offer, and (2) following completion of the Squeeze-Out Procedures, GMO will indirectly acquire up to 5% of the economic interests in the Carlyle Fund by acquiring the limited partnership interests in a limited partnership Carlyle plans to form under the laws of the Cayman Islands (the “LP Interest Acquisition (GMO),” and together with the LP Interest Acquisition (Dalton Group), the “LP Interest Acquisition”; the specific percentage of LP interests to be acquired by GMO remains undetermined) (Note 2). The limited partnerships (including whether they are the same or different entities) that will be the subject of the acquisition of limited partnership interests in both the LP Interest Acquisition (Dalton Group) and the LP Interest Acquisition (GMO) remain undetermined.

The Offeror, upon entering into the Tender Agreement (GMO), was informed by GMO that the number of Target Shares for which GMO had been entrusted with investment management as the investment manager was 2,237,900 shares (ownership ratio: 10.38%). Furthermore, as this number of shares matched the number stated in Amendment Report No. 4 to the Large Shareholding Report concerning the Target Shares submitted by GMO on August 5, 2024, the Tender Agreement (GMO) was entered into with the understanding that the number of Target Shares for which GMO acts as investment manager under a discretionary investment management agreement was 2,237,900 shares (ownership ratio: 10.38%). Subsequently, on December 26, 2025, the Offeror received notification from GMO that the number of Target Shares for which GMO has been entrusted with investment management as an investment manager was found to be 2,256,100 shares (ownership ratio: 10.46%).

which is 18,200 shares (ownership ratio: 0.08%) more than the 2,237,900 shares (ownership ratio: 10.38%). Consequently, on January 6, 2026, the Offeror entered into an amendment agreement with GMO to amend the Tender Agreement (GMO), which contains the amendment to the number of Target Shares for which GMO, as the investment manager with delegated investment management authority, shall tender under the Tender Agreement (GMO) from 2,237,900 shares (ownership ratio: 10.38%) to 2,256,100 shares (ownership ratio: 10.46%).

<Text omitted>

End.

[Restrictions on Solicitation]

This press release is a press release to announce the Tender Offer to the public and has not been prepared for the purpose of soliciting sales. When offering to sell, please make sure to read the Tender Offer Explanatory Statement regarding the Tender Offer and offer at your own discretion. This press release does not constitute or form part of any offer or solicitation to sell, or any solicitation of offers to purchase any securities, nor shall this press release (or any part thereof) or the fact of its distribution form the basis of any agreement relating to the Tender Offer, nor may it be relied upon in entering into any such agreement.

[Forward-Looking Statements]

This press release may contain expressions related to future outlooks, such as “expect,” “anticipate,” “intend,” “plan,” “believe,” and “assume,” concerning the future business on the part of the Offeror and other companies. These expressions are based on the Offeror’s current business forecast and may change due to future circumstances. The Offeror is not obligated to update these forward-looking statements to reflect actual performance or changes in various circumstances or conditions, and so forth.

[U.S. Regulations]

The Tender Offer will be conducted in accordance with the procedures and information disclosure standards prescribed by Japanese law, while these may differ from the procedures and information disclosure standards in the United States. In particular, the provisions of Article 13 (e) or Article 14 (d) of the U.S. Securities Exchange Act of 1934 (as amended; hereinafter the same) and the related rules stipulated thereunder do not apply to the Tender Offer, and the Tender Offer is not carried out in compliance with these procedures and standards. The financial information included in this press release and its reference documents are based on accounting principles in Japan, and therefore, is not in accordance with the U.S. accounting standards and may not be equivalent to, or comparable with, financial information prepared in accordance with the U.S. accounting standards. In addition, since the Offeror is a corporation incorporated outside the U.S. and all or some of its officers are not U.S. residents, it may be difficult to exercise rights or demands which would be claimed under the U.S. securities laws. It may not be able to bring legal proceedings against a non-U.S. entity or its officers in a court outside of the U.S. for violation of U.S. securities related laws. Furthermore, U.S. courts may not necessarily have jurisdiction over non-U.S. entities and their subsidiaries and affiliates.

Unless otherwise specified, all procedures relating to the Tender Offer are to be conducted entirely in Japanese. All or any part of the document related to the Tender Offer is prepared in the English language and if there is any inconsistency between the English-language documentation and the Japanese-language documentation, the Japanese-language documentation shall prevail.

This press release and its reference documents include “forward-looking statements” as defined in Section 27A of the U.S. Securities Act of 1933 (Securities Act of 1933; as amended) and Section 21E of the Securities Exchange Act (Securities Exchange Act of 1934). The results may significantly differ from those explicitly or implicitly indicated as “forward-looking statements” due to known or unknown risks, or uncertainties, or other causes. Neither the Offeror nor any of its affiliates can provide assurance that such results explicitly or implicitly indicated as “forward-looking statements” will be realized. The “forward-looking statements” in this press release and its reference documents were prepared based on the information held by the Offeror as of today, and unless required by laws and regulations or financial instruments exchange rules, the Offeror, the Target and its affiliates are not obliged to change and/or modify such statements in order to reflect any event or condition in the future.

The Offeror and its affiliates, and the financial advisors of the Offeror, EQT, and the Target; and

the tender offer agent (including their affiliates), may, within the ordinary course of their business and to the extent permitted under Japanese financial instruments and exchange regulations and other applicable laws, and in compliance with the requirements of Rule 14e-5(b) under the U.S. Securities Exchange Act of 1934, purchase or take actions to purchase Target Shares for their own account or for the account of their clients, either before the commencement of the Tender Offer or during the Tender Offer Period, outside of the Tender Offer. Such purchases may be conducted at market prices through market transactions or at prices determined through negotiations outside the market. If information regarding such purchases is disclosed in Japan, it will also be disclosed on the English-language website of the entity that conducted the purchase or its affiliates.

[Other Countries]

Certain countries or regions may impose legal restrictions on the announcement, publication, or distribution of this press release. In such cases, please be aware of and comply with those restrictions. This shall not constitute a solicitation of an offer to purchase or an offer to sell shares in connection with the Tender Offer, and shall be deemed to be merely the distribution of materials for information.